High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the southeastern cancer study group

High antileukemic activity of sequential

High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias : Results of a clinical Phase II study

✍ Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard Wörmann; Thomas Bü 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

Department of Heremission whereas 5 patients (23%) succumbed to early death and 3 patients (14%) matology and Oncology, Go ¨ttingen, Germany. did not respond. Blood counts recovered at a median of 33.5 days after the start 2 Westfa ¨lische Wilhelms University, Department of treatment and complete r